Breaking News

Regeneron Acquires Sanofi Ophthalmology Programs

May 3, 2013

Deal worth as much as $50 million, plus royalties

Regeneron Pharmaceuticals has expanded its ophthalmology portfolio, acquiring exclusive rights to two antibodies invented at Regeneron and previously part of its collaboration with Sanofi. The antibodies target the PDGF (platelet derived growth factor) family of receptors and ligands in ophthalmology and all other indications. Antibodies to PDGF and ANG2 are currently in preclinical development for use in ophthalmology.
Regeneron will pay Sanofi $10 million upfront, as much as $40 million in development milestones, and royalties on sales. With respect to ANG2 antibodies in ophthalmology, Regeneron will pay Sanofi $10 million upfront, a potential $5 million development milestones, and royalties on sales.
Regeneron and Sanofi will continue to develop Antibodies to ANG2 outside of ophthalmology under their antibody collaboration agreement, including REGN910 (SAR 307746), which is currently in Phase I development in patients with advanced malignancies.

blog comments powered by Disqus
  • Cold Chain Packaging Trends

    Cold Chain Packaging Trends

    Kristin Brooks, Contract Pharma||February 4, 2016
    Susan Li of UPS discusses supply chain trends, challenges, and packaging innovations

  • Packaging Equipment Trends Preview

    Packaging Equipment Trends Preview

    Kristin Brooks, Contract Pharma||January 26, 2016
    Christian Treitel of Bosch Packaging Technology discusses trends and capabilities

  • Filings Update

    Filings Update

    December 1, 2015
    Roche, Pfizer, Janssen, BMS and more

  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.

  • Cold-Chain Logistics & The Central Lab

    Kristin Brooks, Associate Editor||January 28, 2016
    Eric Hayashi of LabConnect discusses safety measures to ensure sample integrity

  • A Look at DCAT Week ‘16

    Tim Wright, Editor||January 28, 2016
    On the pulse of the pharmaceutical manufacturing value chain, DCAT Week ‘16 will deliver top-flight education programs and networking events.